Intergenically Spliced Chimeric RNAs in Cancer.
Intergenically Spliced Chimeric RNAs in Cancer.
复制标题
DOI：
10.1016/j.trecan.2016.07.006
复制
发表时间：
2016-09
期刊：
影响因子：
18.4
通讯作者：
Li H
中科院分区：
文献类型：
--
作者：
Jia Y;Xie Z;Li H
基因融合及其编码产物（融合RNA和蛋白质）被视为癌症的标志之一。传统上，它们被认为仅仅是由染色体重排产生的。然而，最近发现的相邻基因之间的反式剪接和顺式剪接事件表明，有其他机制来产生嵌合融合RNA，而没有相应的DNA变化。此外，嵌合RNA已在正常生理学中检测到，这使得融合在癌症检测和治疗中的使用复杂化。另一方面，“基因间剪接”融合RNA代表了一种新的生物标志物和治疗靶点。在这里，我们回顾了目前的知识嵌合RNA和癌症检测和治疗的影响，并讨论了突出的问题，该领域的进步。
Gene fusions and their encoded products (fusion RNAs and proteins) are viewed as one of the hallmarks of cancer. Traditionally, they were thought to be generated solely by chromosomal rearrangements. However, recent discoveries of trans-splicing and cis-splicing events between neighboring genes, suggest that there are other mechanisms to generate chimeric fusion RNAs without corresponding changes in DNA. In addition, chimeric RNAs have been detected in normal physiology, complicating the use of fusions in cancer detection and therapy. On the other hand, “intergenically spliced” fusion RNAs represent a new repertoire of biomarkers and therapeutic targets. Here, we review current knowledge on chimeric RNAs and implications for cancer detection and treatment, and discuss outstanding questions for the advancement of the field.